Adding losartan to lisinopril therapy in patients with hypertension: Assessment by 24-hour ambulatory blood pressure monitoring

Current Therapeutic Research - Clinical and Experimental

Volumn 60, Issue 6, 1999, Pages 326-334

  Fogari, Roberto ^a   Zoppi, Annalisa ^a   Corradi, Luca ^a   Poletti, Luigi ^a   Piazza, Elena ^a   Mugellini, Amedeo ^a   Pilun, Emanuela Broglia ^a   Preti, Paola ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Essential hypertension; Lisinopril; Losartan; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; LISINOPRIL; LOSARTAN; RENIN;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG MIXTURE; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE BLIND PROCEDURE;

EID: 0032842572     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(99)80009-5     Document Type: Article

References (25)

1. Mooser V, Nussberger J, Juillerat L, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE-inhibition. J Cardiovasc Pharmacol. 1990;15:276-282.
2. Juillerat L, Nussberger J, Menard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990;16:564-572.
3. Gadsboll N, Nielsen MD, Giese J, et al. Diurnal monitoring of blood pressure and the renin-angiotensin system in hypertensive patients on long-term angiotensin converting enzyme inhibition. J Hypertens. 1990;8:733-740.
4. Van Den Meiracker AH, Man in 't Veld AJ, Admiral PJJ, Ritsema van Eck HJ. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response? J Hypertens. 1992;10:803-812.
5. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens. 1984;2:277-284.
6. Urata H, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
7. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens. 1994;12(Suppl):17-22.
8. Azizi M, Chatellier G, Guyene T, et al. Additive effects of combined angiotensin converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium depleted normotensives. Circulation. 1995;92:825-834.
9. Boomsma F, De Bruyn JHB, Derkx FHM, Shalekamp MADH. Opposite effects of captopril on angiotensin I converting enzyme "activity" and "concentration": Relation between enzyme: inhibition and long-term blood pressure response. Clin Sci. 1981;60:4911-4918.
10. Cachofeiro V, Maeso R, Rodrigo E, et al. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension. 1995;26:236-243.
11. Zhang X, Xie YW, Nasjletti A, et al. ACE-inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation. 1997;95:176-182.
12. Jaiswal N, Diz DI, Tallant EA, et al. The nonpeptide angiotensin II antagonist DUP 753 is a potent stimulus for prostacyclin synthesis. Am J Hypertens. 1991;4:228-233.
13. Azizi M, Guyenne TT, Chatellier G, et al. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension. 1997;29:634-640.
14. Menard J, Campbell DJ, Azizi M, Gonzales MF. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight and renin in spontaneously hypertensive rats. Circulation. 1997;96:3072-3078.
15. Richer C, Bruneval P, Menard J, Giudicelli JF. Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats. Hypertension. 1998;31:692-698.
16. Groppelli A, Omboni S, Ravogli A, et al. Validation of the Spacelabs 90202 and 90207 devices for ambulatory blood pressure monitoring by comparison with intra-arterial resting and ambulatory measurements. J Hypertens. 1991;9(Suppl):S334-S355.
17. Nussberger J, Brunner DB, Waeber B, Brunner HR. In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II. Life Sci. 1988;42:1683-1688.
18. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: A paradigm shift? Circulation. 1994;89:458-470.
19. Stoll M, Steckelings UM, Paul M, et al. The ang AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-657.
20. Fernandez LA, Caride VJ, Stromberg C, et al. Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol. 1994;24:937-940.
21. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96:2515-2520.
22. Levy BI, Benessiano J, Henrion D, et al. Chronic blockade of AT2-subtype receptors prevents the effect of Ang II on the rat vascular structure. J Clin Invest. 1996;98:418-425.
23. Iyer SN, Chappel MC, Averill DB, et al. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension. 1988;31:699-705.
24. Chappel MC, Tallant EA, Brosnihan KB, Ferrario CM. Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC 3. 4. 24. 15) in vascular smooth muscle cells. J Vasc Med Biol. 1994;5:129-137.
25. Tan F, Morris PW, Skidgel RA, Erdos EG. Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C). Similarity to both serine carboxypeptidase and prolylendopeptidase families. J Biol Chem. 1993;268:16631-16638.